Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00132028 · ClinicalTrials.gov registry record · Phase 2
Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma
A Phase 2 study of Recurrent Adult Hodgkin Lymphoma and Adult Lymphocyte Depletion Hodgkin Lymphoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT00132028 is a Phase 2 study of Recurrent Adult Hodgkin Lymphoma and Adult Lymphocyte Depletion Hodgkin Lymphoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 27 participants, roughly in line with the 29-participant average among 4 other Recurrent Adult Hodgkin Lymphoma trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT00132028, a Phase 2 study of Recurrent Adult Hodgkin Lymphoma and Adult Lymphocyte Depletion Hodgkin Lymphoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well vorinostat works in treating patients with relapsed or refractory advanced Hodgkin's lymphoma. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG vorinostat
Study Locations (1)
Texas
- Southwest Oncology Group (SWOG) Research Base - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2005-09 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00132028
The ClinicalTrials.gov registry entry for NCT00132028 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 29-participant average among 4 other Recurrent Adult Hodgkin Lymphoma trials with a reported enrollment target. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Recurrent Adult Hodgkin Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00132028 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00132028 about?
NCT00132028 is a clinical study titled "Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma". This phase II trial is studying how well vorinostat works in treating patients with relapsed or refractory advanced Hodgkin's lymphoma. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT00132028?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2005-09. Estimated completion is 2009-05.
What conditions does trial NCT00132028 study?
This clinical trial studies the following conditions: Recurrent Adult Hodgkin Lymphoma, Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma.
What interventions are being tested in trial NCT00132028?
The interventions under investigation include: laboratory biomarker analysis (OTHER), vorinostat (DRUG).
Who is sponsoring clinical trial NCT00132028?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00132028 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Adult Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
COMPLETED · Phase 2
-
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma
COMPLETED · Phase 1
-
Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma
COMPLETED · Phase 1
Explore more on PlainTrial
Recurrent Adult Hodgkin Lymphoma
All registered trials for this condition
Adult Lymphocyte Depletion Hodgkin Lymphoma
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.